key: cord-1022409-tug5glq6
authors: Racine, E.; Boivin, G.; Longtin, Y.; McCormack, D.; Decaluwe, H.; Savard, P.; Cheng, M. P.; Hamelin, M.-E.; Tadount, F.; Adams, K.; Bourdin, B.; Nantel, S.; Gilca, V.; Corbeil, J.; De Serres, G.; Quach, C.
title: The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers.
date: 2022-02-10
journal: nan
DOI: 10.1101/2022.02.10.22269967
sha: 38baa491f1337d95e00bfd9abe3a7a26a49a4615
doc_id: 1022409
cord_uid: tug5glq6

Background : Understanding the immune response to natural infection by SARS-CoV-2 is key to pandemic management, especially in the current context of emerging variants. Uncertainty remains regarding the efficacy and duration of natural immunity against reinfection. Method : We conducted an observational prospective cohort study in Canadian healthcare workers (HCWs) with a history of PCR-confirmed SARS-CoV-2 infection to : (i) measure the average incidence rate of reinfection and (ii), describe the serological immune response to the primary infection. Results : We detected 5 cases of reinfection over 14 months of follow-up, for a reinfection incidence rate of 3.3 per 100 person-years. Median duration of seropositivity was 420 days in symptomatics at primary infection compared to 213 days in asymptomatics (p<0.0001). Other variables associated with prolonged seropositivity for IgG against the spike protein included age 55 and above, obesity, and non-Caucasian ethnicity. Summary : Among healthcare workers, the incidence of reinfection with SARS-CoV-2 following a primary infection remained rare, although our analysis predates the circulation of the Omicron variant.

Since its appearance in Wuhan (China) in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease (COVID- 19) spread into a global pandemic, leading to more than 340 million reported cases and over 5.5 million confirmed deaths as of January 24 th 2022, according to the WHO [1] .

COVID-19 continues to exert a high burden on healthcare systems across the world because of effective interhuman transmissibility and clinical illness that leads to hospitalization in severe cases. To curb virus transmission and avoid overwhelming healthcare systems, different non-pharmacological interventions (NPIs) have been implemented, including physical/social distancing, improved hand hygiene adherence, mask mandates, business and school closures, city-wide lockdowns, and international border closures. While these mitigation measures have caused significant economic, social, and health-related adverse effects [2] , they remain necessary until a sufficient proportion of individuals become protected against SARS-CoV-2 infection. With the recent emergence of the highly transmissible Delta and Omicron variants, this proportion could be higher than 90% [3] .

Protection against SARS-CoV-2 infection may be acquired by recovering from a previous episode of natural infection. However, the duration of natural immunity is unknown and infection of a large proportion of the population may not suffice to achieve collective immunity, in particular when facing emerging variants. This is of concern because of unequal vaccine distribution across the world [4] and significant level of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint vaccine hesitancy in Europe and the United States [5] . Therefore, it is important to determine if individuals with a history of PCR-confirmed SARS-CoV-2 infection are protected against symptomatic reinfection and viral shedding and if so, how long this protection lasts.

Several large-scale prospective and retrospective cohort studies have recently addressed SARS-CoV-2 reinfection epidemiology in both healthcare workers [6] [7] [8] [9] and general populations [10] [11] [12] [13] [14] [15] [16] . All these studies report that reinfections are generally uncommon events (less than 1% risk over several months following primary infection) and that a history of previous infection confers protection against future infection (ranging from 82% to 93%). This protection persists for at least a few months, but its long-term duration remains largely unknown. Moreover, investigations are warranted to determine if vaccination alters the acquired natural immunity against SARS-CoV-2. Recent evidence suggests that the risk of reinfection could be significantly higher with the new Omicron variant compared to previous variants [17] .

The primary objective of the REinfection in COVID-19 Estimation of Risk (RECOVER) study is to estimate the incidence rate of reinfection with SARS-CoV-2 in a population of healthcare workers (HCWs) with a history of PCR-confirmed SARS-CoV-2 infection, acquired during the first or second wave of the pandemic. We describe in detail all cases of reinfection detected during the first year of the study, estimate the reinfection incidence rate in unvaccinated HCWs, describe the serological response following infection and provide an in-depth profile of a cohort of previously infected HCWs.

The RECOVER study is an observational prospective cohort study of HCWs with a history of PCR-confirmed SARS-CoV-2 infection. Eligible HCWs comprised any professional working in the Greater Montreal (Quebec, Canada) area healthcare facilities, including physicians, nurses, patient attendants, therapists, technicians, maintenance employees, food workers, administrative personnel, and researchers. Prospective participants were excluded if: (i) they were no longer working in a healthcare setting or had been furloughed as a preventive measure at the time of enrolment, (ii) they were not fluent in either French or English, (iii) they had no access to a cell phone or Internet for follow-up procedures, (iv) they were participating in a clinical trial for preventive treatment for COVID-19 and/or (v) they received a COVID-19 vaccine prior to enrolment. Planned follow-up period was at least 12 months for all participants and was extended to 18 months for participants that remained unvaccinated. A timeline of the study is presented in Figure 1 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint

Sample size was designed to measure a 3% risk of reinfection 1 over 12 months with 95% confidence of a ±1.5% precision (precision equals half the estimated risk). Accounting for an estimated 10 to 15% loss to follow-up, a sample size of 570 HCWs was deemed optimal [18] .

Upon enrolment (day 0; D0), baseline demographic, clinical and biological data were obtained from each participant. Demographic data included date of birth, biological sex at birth, ethnicity, workplace, and profession. Clinical data included height, weight, medical history, medication, lifestyle information, and recent vaccination history. Detailed information about original COVID-19 illness was collected, including symptomatology, duration of symptoms, date of first positive PCR test, and need for hospitalization/advanced treatment. Blood samples were drawn at D0 for assessment of immune response to the original infection.

Follow-up 1 At study design, estimates of reinfection risk were obtained from literature on other human coronaviruses, which suggested a higher risk of reinfection than what has since been observed with SARS-CoV-2. Vaccines were being developed and were not available at the time of study design.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2022. ; symptomology, clinical course). For the first 30 participants 2 who reported a significant exposure, a follow-up visit was scheduled four to seven days post exposure to collect an NP swab to ascertain asymptomatic reinfection.

Anonymized data was collected, stored, and managed using the secure web-based application REDCap [19] . Consent was obtained at enrolment and reviewed at each Cox regressions modeled the hazard (probability per unit time) to obtain a negative serology test. Therefore, a hazard ratio (HR) higher than 1 represents a shorter average duration of seropositivity.

Primary outcomes were possible, probable, or confirmed reinfection with SARS-CoV-2, in absence of vaccination. Possible reinfection was defined as a positive PCR test less than 90 days after first infection. Probable reinfection was defined as a positive PCR test 90 days or more after the first positive test. Confirmed reinfection required either (i) 2 This number was limited to 30 because of budget constraints.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint evidence of infection by a known distinct variant or (ii) a variant that was not circulating at time of first infection or (iii) confirmation that the two strains were different by whole genome sequencing. Participants that received any vaccination against SARS-CoV-2 during follow-up were right-censored for reinfection outcomes at reception of the first dose. Our secondary outcome was serology status for IgG against the receptor-binding domain (RBD) of the SARS-CoV-2 spike as a function of time since primary infection, in participants that remained unvaccinated 3 .

Qualitative reverse-transcriptase PCR (RT-PCR) was performed on all samples. Upon . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint RBD assay had a sensitivity of 95% and specificity of 100%. Participants were considered seropositive if the optical density (OD) was higher than the mean OD of negative controls 4 plus three standard deviations.

The demographic characteristics of our cohort are presented in Table 1 . Participants were in majority female (biological sex at birth; n=472, 83.0%) and Caucasian (n=451, 79.3%). Median age was 42 years (IQR 25-75: 32-50) and ranged from 18 to 75 years.

Most HCWs worked in acute-care hospitals (n=308, 54.1%) or in public long-term care facilities (n=139, 24.4%). The most common reported profession was nurse/paramedic (n=230, 40.4%), followed by patient care attendant (n=73, 12.8%) and physician/medical resident (n=67, 11.8%).

Baseline medical/lifestyle data are presented in Table 2 . A total of 82 HCWs (14.4%) reported at least one medical condition considered a risk factor for severe COVID-19

illness per CDC guidelines [20] . Most HCWs were either overweight (25 ≤ BMI < 30 kg/m 2 ; n=181, 31.8%) or obese (BMI ≥ 30 kg/m 2 ; n=143, 25.1%), while only 8 HCWs were underweight (BMI < 18.5 kg/m 2 ; 1.4%). Most participants (n=526, 92.4%) did not smoke tobacco products (including vaping products), cannabis or other drugs. Nearly a 4 Controls were negative sera obtained in the pre-pandemic era.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint third of participants (n=182, 32.0%) reported regular vitamin D intake, with median weekly intake of 7000 IU.

Data regarding primary infections are reported in Table 3 . In most participants (n=541, 

We detected 5 cases of probable reinfection between August 17 th , 2020, and October 19 th , 2021; their characteristics are reported in Table 4 . We did not detect any possible nor . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint confirmed reinfection. One participant reported a recurrence of acute symptoms 6 months after the first illness, but never tested positive again. Although this episode was suggestive of reinfection, it was excluded from analysis as it did not meet our primary outcome definitions. Cumulative time at risk for probable reinfection while unvaccinated amounted to 54 675 person-days, for an average reinfection incidence rate of 3.3 (1.1 -7.8) per 100 person-year.

Three out of five probable reinfections (60%) were asymptomatic, while only 5% of initial infections were asymptomatic (Fisher exact test p-value = 0.0013); no reinfections required hospitalization. One asymptomatic reinfection was detected through screening at enrolment, one was detected at the workplace and the third was detected through contact tracing. PCRs positive for reinfection generally reported low viral loads (Table 4 ).

Significant exposure within two weeks before the 2 nd positive PCR was reported in three out of five (60%) reinfection cases.

The crude probability of remaining at risk for probable reinfection as a function of time since considered at risk is shown in Figure 2 Twenty-nine participants did not contribute any person-time at risk, explaining the vertical drop of survival at D0: one participant was identified as reinfected through screening at D0 and the other 28 were vaccinated within 90 days from their first positive PCR. Overall, removal from the at-risk pool for probable reinfection while unvaccinated was mostly due to vaccination rather than reinfection itself.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 ). The median duration of seropositivity was 420 days (95% CI: 406 -Infinity) in initially symptomatic participants, compared to 213 days (95% CI: 161 -Infinity) in initially asymptomatic participants (p<0.0001). Kaplan-Meier curves further stratified according to number of symptoms are shown in Figure 4 , panel C; mean number of self-reported symptoms was between 7 and 8. Individuals with 8 symptoms or more, defined as polysymptomatic, remained seropositive longer than individuals with 1 to 7 symptoms, defined as paucisymptomatic (p<0.0001). The median duration of seropositivity in the polysymptomatic category was undefined 6 , while median duration of seropositivity in paucisymptomatic category was 420 days (95% CI: 329 -Infinity). Finally, Kaplan-Meier curves stratified by ethnicity are shown in Figure 4 , panel D. We observed that non-Caucasian participants remained seropositive significantly longer than Caucasians (p = 0.0031). Median duration of seropositivity in 5 Assuming all participants were seropositive at time of primary infection. 6 Because less than 50% of polysymptomatics became seronegative during follow-up.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. 7 Because less than 50% of non-Caucasians became seronegative during follow-up.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint Fifty-six participants (9.8%) were either lost to follow-up or withdrew from the study at the time of interim analysis. [7] . Another English cohort study in HCWs by Lumley et al. reported a reinfection incidence rate of 0.47 per 100 person-years [9] . Other studies investigated reinfection rates in the general population. Abu-Raddad et al. estimated the reinfection incidence rate in Qatar at 1.3 per 100 person-years, using a cohort of laboratory-confirmed primary infections [22] . In a Danish population-level observational study by Hansen et al., the reinfection incidence rate was estimated at 2.0 per 100 person-years [12] . Other studies reported risk of reinfection in various cohorts [6, [23] [24] [25] , but did not report incidence rates 8 . It is important to note that the reinfection rates observed in these studies predate the Omicron wave and depend on the incidence 8 Peer-reviewed reinfection incidence rates cited in this section were estimated before the spread of the omicron variant; they may not reflect reinfection incidence rates during the first omicron wave.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint rates in the general population of each region/country, which limits inter-study comparability.

Our measured incidence rate of self-reported significant exposure was approximately 14 times higher than our reinfection incidence rate. However, it remains unclear if this rate ratio constitutes a reliable measure of protection because: (i) we did not have a cohort naïve to SARS-CoV-2 to establish baseline comparison values for infection and significant exposure incidence rates and (ii) it is likely that many significant exposure events were either unreported or unrecognized by participants.

Our Kaplan-Meier analysis shows that the overall probability of remaining seropositive up to 300 days after the initial infection is approximately 70% in the absence of vaccination. Duration of seropositivity was significantly positively correlated with the number of symptoms at primary infection; duration of seropositivity was longest in polysymptomatics and shortest in asymptomatics. Duration of seropositivity was significantly longer in non-Caucasian participants compared to Caucasian participants.

Although not explained in our regression models, we hypothesize that the effect of ethnicity on duration of seropositivity could be attributed to profession, workplace and household size [26, 27] , which could lead to more re-exposures without symptomatic disease that thus went undetected. Finally, it remains uncertain whether positive serology constitutes a strong correlate of protection [28] . However, emerging evidence indicates that higher levels of IgG seem correlated with higher neutralization capacities [7, 12, 29] .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint Our epidemiological and serological evidence supports the hypothesis that primary infection by SARS-CoV-2 confers significant protection against reinfection for at least several months, and up to the spread of the Omicron variant.

Our study has several strengths. First, our prospective cohort is representative of the population of HCWs in the Greater Montreal area, through our multicentric recruitment process and permissive eligibility criteria. Participants were closely monitored during follow-up, with frequent electronic questionnaires and in-person visits, which decreases recall/memory bias. Data collection was exhaustive and included a wealth of demographic, clinical, and biological information, allowing adjustment/stratification for many potential confounders and effect measure modifiers. HCWs constituted an ideal population for studying reinfection risk and protection conferred by natural infection because they are more frequently exposed to SARS-CoV-2 than the general population, increasing the validity of our measurements. Finally, most participants remained enrolled in the study, limiting selection bias from loss to follow-up.

Our study nevertheless has some limitations. First, we observed a very small number of reinfections, hence limiting statistical power. Specifically, we could not determine whether demographic and/or clinical individual characteristics were associated with an increased or decreased reinfection incidence rate. It is also likely that we missed cases of asymptomatic reinfections, since we did not systematically screen all participants with NP swabs on a regular basis (e.g., every 2 weeks). Participants were randomly swabbed only twice during the entire follow-up, which could allow for asymptomatic reinfections . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ;

to remain undetected. Our measured reinfection incidence rate thus probably underestimates the true reinfection rate, especially if asymptomatic reinfections are PCRpositive for only a short time. Our study could not identify any case of confirmed reinfection by genetic comparison of viral strains, because material recovered in reinfection swabs was insufficient to allow genome sequencing. These low viral loads suggest that reinfected individuals may be less likely to transmit SARS-CoV-2 to susceptible individuals compared to naïve individuals who become infected [30] , with the caveat that our study was conducted prior to the spread of the Omicron variant.

Vaccines against SARS-CoV-2 became available to participants about 4 months after the initiation of our study. Since participant recruitment was not yet completed when vaccination started, time between enrolment and vaccination was highly heterogeneous, which could impart selection bias. Therefore, we could not calculate a meaningful risk of reinfection in previously infected but unvaccinated individuals over 12 months.

Finally, our cohort is composed mostly of young, female, Caucasian and generally healthy HCWs. This limits the generalizability of our results to other populations, and our capacity to reveal and/or explain possible associations between covariates like sex, age, ethnicity and presence of comorbidities, and our outcomes of reinfection and loss of measurable serum IgG.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; 10 There were no active cancers in our cohort, so this category is not included. 11 Excluding asthma. 12 Includes pregnancy, thalassemia, sickle cell anemia. 13 Includes cannabis/cannabis products.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; 14 Percentage among symptomatic individuals. 15 Two symptomatic individuals did not report duration of symptoms.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 10, 2022. ; Table 4 : Characteristics of reinfection cases. D0 = enrolment. PCR+ = positive PCR test. !" = time interval. Ct = cycle threshold. First positive PCR refers to primary infection; second positive PCR refers to reinfection. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint Figure 1 : Timeline of the RECOVER study, overlayed with variants in circulation during the study period. Enrolment of participants was from August 17 th 2020 to April 8 th 2021. Follow-up period (for the results presented in this paper) was from August 17 th 2020 to October 19 th 2021. Enrolled participants acquired their primary infection between March 6 th 2020 and February 14 th 2021. Approximate periods for circulation of variants were derived from provincial surveillance data. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint Figure 3 : Kaplan-Meier curve for the probability of reporting symptoms attributable to the primary infection as a function of time since primary infection. For participants who reported no residual symptoms at enrolment (D0), the duration of symptoms was collected by questionnaire at D0. For participants who reported residual symptoms at D0, we considered them as symptomatic until they declared complete resolution of symptoms at a quarterly visit.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 10, 2022. ; https://doi.org/10.1101/2022.02.10.22269967 doi: medRxiv preprint

WHO Coronavirus (COVID-19) Dashboard. Available at

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

Omicron variant and booster COVID-19 vaccines

Unequal distribution of COVID-19 vaccine: A looming crisis

Europe and United States vaccine hesitancy': leveraging strategic policy for 'Infodemic' on COVID-19 vaccines

Protection of healthcare workers against SARS-CoV-2 reinfection

SARS-CoV-2 infection rates of antibodypositive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

SARS-CoV-2 re-infection risk in Austria

Risk of SARS-CoV-2 reinfection in a university student population

Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study

Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

Pratical Issues in Calculating the Sample Size for Prevalence Studies

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

COVID-19 and Your Health

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

COVID-19 re-infection

COVID-19 reinfection in healthcare workers: a case series

Government of Canada SC. Montréal -A data story on Ethnocultural Diversity and Inclusion in Canada

The contribution of immigrants and population groups designated as visible minorities to nurse aide, orderly and patient service associate occupations

A correlate of protection for SARS-CoV-2 vaccines is urgently needed

Correlates of protection from SARS-CoV-2 infection

What reinfections mean for COVID-19